Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
$4.34
-$0.06(-1.69%)
At close: 4:00 PM EST
$4.34
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)483.50K
Market Cap
$116.99M
Enterprise Value$457.26M
Total Cash (Recent Filing)$3.46M
Total Debt (Recent Filing)$45.77M
Price to Earnings (P/E)―
Beta3.31
Next Earnings
Mar 12, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding34,008,350
10 Day Avg. Volume544,068
30 Day Avg. Volume483,504
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.18
Price to Sales (P/S)0.57
P/FCF Ratio-0.37
Enterprise Value/Market Cap3.91
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit5.32K
Enterprise Value/Ebitda13.72
Forecast
1Y Price Target
$23.00Price Target Upside429.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital InjectionAgenus has agreed to sell its California-based CMC manufacturing facilities to Zydus, providing an essential $91M injection of capital to administer the BATTMAN Phase 3 trial.
Clinical Trial SuccessThe company reported positive data from the Phase 1b pan-tumor trial, indicating an impressive 39% 2-year median OS in late-line patients.
Regulatory ApprovalFrance's medicine agency authorized compassionate access for bot/bal in patients with metastatic MSS-CRC without LMs, signaling early positive regulatory sentiment toward bot/bal's safety and efficacy.
Bears Say
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $116.99M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Mar 12, 2026 which is in 82 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 10, 2025. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $2.197 by -$0.257.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is 0.47.
How many shares outstanding does Agenus have?
Agenus has 34,008,350 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of $1.94 in its last earnings report, missing expectations of $2.197. Following the earnings report the stock price went up 5.779%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (429.95% Upside)
$23.00 (429.95% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Company Description
Agenus
Agenus (AGEN) is a biotechnology company focused on the discovery and development of immuno-oncology therapies to treat cancer. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary technology platforms to create a diverse pipeline of product candidates, which includes immune checkpoint modulators, cancer vaccines, and other immunotherapeutics. Agenus aims to harness the body's immune system to fight cancer, with a commitment to advancing novel therapies that can improve patient outcomes.
AGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.View all AGEN earnings summariesAGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(429.95% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
Oncolytics Biotech
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
2.14% Insiders
11.70% Mutual Funds
5.03% Other Institutional Investors
76.84% Public Companies and
Individual Investors